Disease‐burden‐adapted immunotherapy protocol for primary refractory or high‐risk relapsed pediatric acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Disease‐burden‐adapted immunotherapy protocol for primary refractory or high‐risk relapsed pediatric acute lymphoblastic leukemia

Published:2024-07-29 Issue:8 Volume:8 Page:
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:HemaSphere

Author:

Khan Sanaa¹,VP Krishnan²,Krishnan Yamini²,Sainulabdin Gazel²,Pal Somdipa²,Mathews Rincy²,Kataria Darshan¹,Sehgal Kunal³,Kanvinde Purva⁴,Harshaprasad Lashkari⁵,Bodhanwala Minnie⁶,Agarwal Bharat¹,Pandrowala Ambreen¹,Hiwarkar Prashant¹^ORCID

Affiliation:

1. Department of Blood and Marrow Transplant Bai Jerbai Wadia Hospital for Children Mumbai India

2. Department of Pediatric Hematology, Oncology and Bone Marrow Transplantation MVR Cancer Centre Kozhikode India

3. Sehgal Path Lab Mumbai India

4. Department of Pediatric Haematology‐Oncology Bai Jerbai Wadia Hospital for Children Mumbai India

5. Department of Paediatric Haematology‐Oncology Kasturba Medical College Mangalore India

6. Department of Pediatrics Bai Jerbai Wadia Hospital for Children Mumbai India

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hem3.111

Reference17 articles.

1. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials

2. Efficacy and safety of a bortezomib and reduced‐intensity cytarabine‐based protocol, TMC ALLR1, for relapsed childhood ALL in India

3. Minimal Residual Disease Prior to and After Haematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant?

4. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia

5. Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia